Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep/Oct;63(5):644-649.
doi: 10.1097/MAT.0000000000000627.

Fourteen Day In Vivo Testing of a Compliant Thoracic Artificial Lung

David J Skoog  1 , Joshua R Pohlmann, David S Demos, Christopher N Scipione, Amit Iyengar, Rebecca E Schewe, Ahmed B Suhaib, Kelly L Koch, Keith E Cook
Affiliations

Fourteen Day In Vivo Testing of a Compliant Thoracic Artificial Lung

David J Skoog et al. ASAIO J. 2017 Sep/Oct.

Abstract

The compliant thoracic artificial lung (cTAL) has been studied in acute in vivo and in vitro experiments. The cTAL's long-term function and potential use as a bridge to lung transplantation are assessed presently. The cTAL without anticoagulant coatings was attached to sheep (n = 5) via the pulmonary artery and left atrium for 14 days. Systemic heparin anticoagulation was used. Compliant thoracic artificial lung resistance, cTAL gas exchange, hematologic parameters, and organ function were recorded. Two sheep were euthanized for nondevice-related issues. The cTAL's resistance averaged 1.04 ± 0.05 mmHg/(L/min) with no statistically significant increases. The cTAL transferred 180 ± 8 ml/min of oxygen with 3.18 ± 0.05 L/min of blood flow. Except for transient surgical effects, organ function markers were largely unchanged. Necropsies revealed pulmonary edema and atelectasis but no other derangements. Hemoglobin levels dropped with device attachment but remained steady at 9.0 ± 0.1 g/dl thereafter. In a 14 day experiment, the cTAL without anticoagulant coatings exhibited minimal clot formation. Sheep physiology was largely unchanged except for device attachment-related hemodilution. This suggests that patients treated with the cTAL should not require multiple blood transfusions. Once tested with anticoagulant coatings and plasma resistant gas exchange fiber, the cTAL could serve as a bridge to transplantation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Top: The side view of the cTAL with inlet and outlet ports labeled. Bottom: The top view with the cTAL inlet taper angle labeled with θH.
Figure 2
Figure 2
The arterial PO2, PCO2, and MAP.
Figure 3
Figure 3
The cTAL resistance and blood flow rate.
Figure 4
Figure 4
Thrombus formation in the explanted cTALs after 14 days of use. Top: The top view. Middle: The side view of the non-taped side. Bottom: The side view of the taped side with the tape labeled.
Figure 5
Figure 5
The cTAL oxygen transfer rate (VO2), cTAL inlet SO2, and cTAL outlet SO2.
See this image and copyright information in PMC

Comment in

References

    1. Association AL. Lung disease data: 2008. Focus: Clean Air and Lung Disease. 2008 Retreived from http://wwwlungusaorg.
    1. Valapour M, Paulson K, Smith JM, et al. OPTN/SRTR 2011 Annual Data Report: Lung. Am J Transplant. 2013;13:149–177. - PubMed
    1. Javidfar J, Brodie D, Iribarne A, et al. Extracorporeal membrane oxygenation as a bridge to lung transplantation and recovery. J Thorac Cardiovasc Surg. 2012;144(3):716–721. - PubMed
    1. Hayes D, Jr, Kukreja J, Tobias JD, Ballard HO, Hoopes CW. Ambulatory venovenous extracorporeal respiratory support as a bridge for cystic fibrosis patients to emergent lung transplantation. J Cyst Fibros. 2012;11(1):40–45. - PubMed
    1. Mangi AA, Mason DP, Yun JJ, Murthy SC, Pettersson GB. Bridge to lung transplantation using short-term ambulatory extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg. 2010;140(3):713–715. - PubMed